Stock MGNX MACROGENICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company MacroGenics, Inc.

Equities

MGNX

US5560991094

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
14.56 USD +1.32% Intraday chart for MacroGenics, Inc. -6.73% +51.35%
Apr. 26 B. Riley Securities Initiates MacroGenics With Buy Rating, $25 Price Target MT
Apr. 10 North American Morning Briefing : Traders Await -2- DJ

Business Summary

MacroGenics, Inc. is a biopharmaceutical company focused on developing and commercializing monoclonal antibody-based therapeutics for the treatment of cancer. It generates its pipeline of product candidates primarily from its suite of antibody-based technology platforms, which have applicability across broad therapeutic domains. It is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is vobramitamab duocarmazine (vobra duo), an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. Its clinical pipeline includes two product candidates based on its, bispecific DART technology that co-engages both PD-1 and other checkpoint molecules. These candidates include lorigerlimab and tebotelimab. In addition, it is developing MGD024, a bispecific DART molecule. It is also developing various other programs.

Number of employees: 339

Sales per Business

USD in Million2022Weight2023Weight Delta
Collaborative and Other Agreements
49.3 %
119 78.5 % 29 49.3 % -75.70%
Monoclonal Antibody-based Therapeutics
30.5 %
17 11.0 % 18 30.5 % +7.25%
Contract Manufacturing
16.7 %
14 9.2 % 10 16.7 % -29.70%
Government Agreements
2.6 %
2 1.3 % 2 2.6 % -19.08%
Royalty
0.7 %
- - 0 0.7 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
152 100.0 % 59 100.0 % -61.33%

Managers

Managers TitleAgeSince
Scott Koenig FOU
 Founder 71 00-08-13
James Karrels DFI
 Director of Finance/CFO 57 08-04-30
Stephen Eck CTO
 Chief Tech/Sci/R&D Officer 69 20-06-30
Eric Risser COO
 Chief Operating Officer 51 09-02-28
Ezio Bonvini CTO
 Chief Tech/Sci/R&D Officer 70 03-05-31
Jeffrey Peters LAW
 General Counsel 53 15-07-31
Thomas Spitznagel PRN
 Corporate Officer/Principal 57 12-12-31
Lynn Cilinski AUD
 Comptroller/Controller/Auditor 66 03-09-30
Syd Johnson PRN
 Corporate Officer/Principal - 00-12-31

Members of the board

Members of the board TitleAgeSince
Margaret Liu BRD
 Director/Board Member 66 23-01-02
David Stump BRD
 Director/Board Member 74 13-09-18
Edward Hurwitz BRD
 Director/Board Member 60 04-09-30
William Heiden CHM
 Chairman 64 22-05-21
Scott Jackson BRD
 Director/Board Member 60 17-01-24
Scott Koenig FOU
 Founder 71 00-08-13
Federica O’Brien BRD
 Director/Board Member 66 21-02-09
Meenu Chhabra Karson BRD
 Director/Board Member 51 23-01-02
Karen Ferrante BRD
 Director/Board Member 66 17-01-24
Jay Siegel BRD
 Director/Board Member 71 17-11-12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,560,502 60,313,787 ( 96.41 %) 0 96.41 %

Shareholders

NameEquities%Valuation
Bellevue Asset Management AG
15.94 %
9,953,313 15.94 % 147 M $
BlackRock Advisors LLC
9.320 %
5,818,626 9.320 % 86 M $
T. Rowe Price Investment Management, Inc.
9.034 %
5,639,994 9.034 % 83 M $
Armistice Capital LLC
7.323 %
4,572,000 7.323 % 67 M $
Vanguard Fiduciary Trust Co.
6.903 %
4,309,394 6.903 % 63 M $
RA Capital Management LP
6.492 %
4,053,077 6.492 % 60 M $
Frazier Life Sciences Management LP
3.847 %
2,401,704 3.847 % 35 M $
STATE STREET CORPORATION
3.482 %
2,174,022 3.482 % 32 M $
Geode Capital Management LLC
2.249 %
1,404,068 2.249 % 21 M $
Scott Koenig
2.080 %
1,298,675 2.080 % 19 M $

Company contact information

MacroGenics, Inc.

9704 Medical Center Drive

20850-3368, Rockville

+301 251 5172

http://www.macrogenics.com
address MacroGenics, Inc.(MGNX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per Business

Ratings for MacroGenics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
14.56 USD
Average target price
24.8 USD
Spread / Average Target
+70.33%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
MACROGENICS, INC. Stock MacroGenics, Inc.
+51.35% 911M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.73B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. MGNX Stock
  4. Company MacroGenics, Inc.